HIF1α and NFkB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression, and resistance to chemotherapy. In fact, HIF1α and NFkB together regulate transcription of over a thousand genes that, in turn, control vital cellular processes such as adaptation to the hypoxia, metabolic reprograming, inflammatory reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc. Because of this wide involvement they could control in an integrated manner the origin of the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7, and some TLRs, are activated by HIF1α and that, in turn, alarmin receptors strongly activate NFkB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype. Recently, a large number of drugs have been identified that inhibit one or both transcription factors with promising results in terms of controlling tumor progression. In addition, many of these molecules are natural compounds or off-label drugs already used to cure other pathologies. Some of them are undergoing clinical trials and soon they will be used alone or in combination with standard anti-tumoral agents to achieve a better treatment of tumors with reduction of metastasis formation and, more importantly, with a net increase in survival. This review highlights the central role of HIF1a activated in hypoxic regions of the tumor, of NFkB activation and proinflammatory gene expression in transformed cells to understand their progression toward malignancy. Different molecules and strategies to inhibit these transcription factors will be reviewed. Finally, the central role of a new class of deacetylases called Sirtuins in regulating HIF1a and NFkB activity will be outlined. ©2013 Tafani, Pucci, Russo, Schito, Pellegrini, Perrone, Villanova, Salvatori, Ravenna, Petrangeli and Russo.

Modulators of HIF1α and NFkB in cancer treatment: Is it a rational approach for controlling malignant progression? / Tafani, Marco; Bruna, Pucci; Russo, Matteo Antonio; Luana, Schito; Pellegrini, Laura; Giulietta A., Perrone; Villanova, Lidia; Salvatori, Luisa; Ravenna, Linda Ester; Petrangeli, Elisa; Matteo A., Russo. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - ELETTRONICO. - 4 FEB:(2013), pp. 1-12. [10.3389/fphar.2013.00013]

Modulators of HIF1α and NFkB in cancer treatment: Is it a rational approach for controlling malignant progression?

TAFANI, MARCO;RUSSO, Matteo Antonio;PELLEGRINI, Laura;VILLANOVA, LIDIA;SALVATORI, Luisa;RAVENNA, Linda Ester;PETRANGELI, Elisa;
2013

Abstract

HIF1α and NFkB are two transcription factors very frequently activated in tumors and involved in tumor growth, progression, and resistance to chemotherapy. In fact, HIF1α and NFkB together regulate transcription of over a thousand genes that, in turn, control vital cellular processes such as adaptation to the hypoxia, metabolic reprograming, inflammatory reparative response, extracellular matrix digestion, migration and invasion, adhesion, etc. Because of this wide involvement they could control in an integrated manner the origin of the malignant phenotype. Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7, and some TLRs, are activated by HIF1α and that, in turn, alarmin receptors strongly activate NFkB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype. Recently, a large number of drugs have been identified that inhibit one or both transcription factors with promising results in terms of controlling tumor progression. In addition, many of these molecules are natural compounds or off-label drugs already used to cure other pathologies. Some of them are undergoing clinical trials and soon they will be used alone or in combination with standard anti-tumoral agents to achieve a better treatment of tumors with reduction of metastasis formation and, more importantly, with a net increase in survival. This review highlights the central role of HIF1a activated in hypoxic regions of the tumor, of NFkB activation and proinflammatory gene expression in transformed cells to understand their progression toward malignancy. Different molecules and strategies to inhibit these transcription factors will be reviewed. Finally, the central role of a new class of deacetylases called Sirtuins in regulating HIF1a and NFkB activity will be outlined. ©2013 Tafani, Pucci, Russo, Schito, Pellegrini, Perrone, Villanova, Salvatori, Ravenna, Petrangeli and Russo.
2013
cancer; hif1α inhibitors; hypoxia; inflammation; nfkb inhibitors; sirtuin activators
01 Pubblicazione su rivista::01a Articolo in rivista
Modulators of HIF1α and NFkB in cancer treatment: Is it a rational approach for controlling malignant progression? / Tafani, Marco; Bruna, Pucci; Russo, Matteo Antonio; Luana, Schito; Pellegrini, Laura; Giulietta A., Perrone; Villanova, Lidia; Salvatori, Luisa; Ravenna, Linda Ester; Petrangeli, Elisa; Matteo A., Russo. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - ELETTRONICO. - 4 FEB:(2013), pp. 1-12. [10.3389/fphar.2013.00013]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/511563
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 39
  • Scopus 82
  • ???jsp.display-item.citation.isi??? 72
social impact